Literature DB >> 5761912

Prophylaxis of recurrent headache.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5761912      PMCID: PMC1981811     

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  8 in total

1.  CLINICAL TRIAL OF METHYSERGIDE AND OTHER PREPARATIONS IN THE MANAGEMENT OF MIGRAINE.

Authors:  D A CURRAN; J W LANCE
Journal:  J Neurol Neurosurg Psychiatry       Date:  1964-10       Impact factor: 10.154

2.  METHYSERGIDE IN THE MIGRAINE SYNDROME.

Authors:  R B SHEKELLE; A M OSTFELD
Journal:  Clin Pharmacol Ther       Date:  1964 Mar-Apr       Impact factor: 6.875

3.  METHYSERGIDE IN THE PROPHYLAXIS OF MIGRAINE.

Authors:  N SOUTHWELL; J D WILLIAMS; I MACKENZIE
Journal:  Lancet       Date:  1964-03-07       Impact factor: 79.321

4.  LIVER IN REGULATION OF FIBRINOLYTIC ACTIVITY.

Authors:  K N VONKAULLA
Journal:  Lancet       Date:  1964-05-09       Impact factor: 79.321

5.  Use of a new compound, UML-491 (1-methyl-D-lysergic acid butanolamide), in the prevention of various types of headache.

Authors:  J R GRAHAM
Journal:  N Engl J Med       Date:  1960-12-22       Impact factor: 91.245

6.  Migraine headache: its physiology and biochemistry.

Authors:  A M OSTFELD
Journal:  JAMA       Date:  1960-10-29       Impact factor: 56.272

7.  Analysis of symptoms of patients with headaches and their response to treatment with ergot derivatives.

Authors:  M A Barrie; W R Fox; M Weatherall; M I Wilkinson
Journal:  Q J Med       Date:  1968-04

8.  Evaluation of UML-491 in the treatment of vascular headaches. An analysis of the effects of 1-methyl-D-lysergic acid (plus) butanolamide bimaleate (methysergide).

Authors:  A P FRIEDMAN; S LOSIN
Journal:  Arch Neurol       Date:  1961-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.